Welcome to LookChem.com Sign In|Join Free

CAS

  • or

23522-20-5

Post Buying Request

23522-20-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

23522-20-5 Usage

Uses

3-[2-(3,4-Dimethoxyphenyl)ethyl]-2-sulfanylidene-1,3-thiazolidin-4-one is used in preparation of arylmethylene and heterocyclylmethylene thiazolidinediones and analogs as tumor necrosis factor inhibitors.

Check Digit Verification of cas no

The CAS Registry Mumber 23522-20-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,5,2 and 2 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 23522-20:
(7*2)+(6*3)+(5*5)+(4*2)+(3*2)+(2*2)+(1*0)=75
75 % 10 = 5
So 23522-20-5 is a valid CAS Registry Number.
InChI:InChI=1/C13H15NO3S2/c1-16-10-4-3-9(7-11(10)17-2)5-6-14-12(15)8-19-13(14)18/h3-4,7H,5-6,8H2,1-2H3

23522-20-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-1,3-thiazolidin-4-one

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:23522-20-5 SDS

23522-20-5Upstream product

23522-20-5Downstream Products

23522-20-5Relevant articles and documents

USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS

-

Page/Page column 14, (2008/06/13)

The invention relates to the use of compounds of general formula (I), in which R1, R2 and X are as defined in the description for the preparation of pharmaceutical compositions for the treatment of pathologies in which inhibition of the interaction between HIF-1α and p300 is beneficial, in particular as antiangiogenic medicaments for the therapy of solid tumors.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 23522-20-5